Neuropsychiatric disorders and cognitive dysfunction in patients with Cushing's disease

Chinese Medical Journal

Volumn 126, Issue 16, 2013, Pages 3156-3160

  Chen, Yu Fan ^a   Li, Yun Feng ^a   Chen, Xiao ^a   Sun, Qing Fang ^a  

^a SHANGHAI JIAO TONG UNIVERSITY   (China)

Author keywords

Cognitive symptoms; Cushing's disease; Glucocorticoids; Hippocampal; Psychology

Indexed keywords

GLUCOCORTICOID; GLUCOCORTICOID RECEPTOR; GLUTAMIC ACID; HYDROCORTISONE; NEUROTROPHIC FACTOR;

ANXIETY DISORDER; BASAL GANGLION; BRAIN ATROPHY; COGNITIVE DEFECT; CUSHING DISEASE; DEPRESSION; DISEASE ASSOCIATION; GENE EXPRESSION; GLUCOSE UTILIZATION; HIPPOCAMPUS; HUMAN; IMPULSIVENESS; MENTAL DISEASE; MENTAL INSTABILITY; MOOD DISORDER; NERVOUS SYSTEM DEVELOPMENT; NEUROPSYCHIATRY; REVIEW; SIGNAL TRANSDUCTION;

BRAIN-DERIVED NEUROTROPHIC FACTOR; COGNITION DISORDERS; GLUCOCORTICOIDS; HIPPOCAMPUS; HUMANS; MENTAL DISORDERS; NEUROGENESIS; PITUITARY ACTH HYPERSECRETION; QUALITY OF LIFE; SIGNAL TRANSDUCTION;

EID: 84882250286     PISSN: 03666999     EISSN: None     Source Type: Journal    
DOI: 10.3760/cma.j.issn.0366-6999.20130944     Document Type: Review

References (43)

1. Clayton RN, Raskauskiene D, Reulen RC, Jones PW. Mortality and morbidity in Cushing's disease over 50 years in Stoke-on-Trent, UK: audit and meta-analysis of literature. J Clin Endocrinol Metab 2011; 96: 632-642.
2. Dorn LD, Burgess ES, Friedman TC, Dubbert B, Gold PW, Chrousos GP. The longitudinal course of psychopathology in Cushing's syndrome after correction of hypercortisolism. J Clin Endocrinol Metab 1997; 82: 912-919.
3. van Aken MO, Pereira AM, Biermasz NR, van Thiel SW, Hoftijzer HC, Smit JW, et al. Quality of life in patients after long-term biochemical cure of Cushing's disease. J Clin Endocrinol Metab 2005; 90: 3279-3286.
4. Tiemensma J, Biermasz NR, Middelkoop HA, van der Mast RC, Romijn JA, Pereira AM. Increased prevalence of psychopathology and maladaptive personality traits after long-term cure of Cushing's disease. J Clin Endocrinol Metab 2010; 95: E129-E141.
5. Biermasz NR, Joustra SD, Donga E, Pereira AM, van Duinen N, van Dijk M, et al. Patients previously treated for nonfunctioning pituitary macroadenomas have disturbed sleep characteristics, circadian movement rhythm, and subjective sleep quality. J Clin Endocrinol Metab 2011; 96: 1524-1532.
6. Hook JN, Giordani B, Schteingart DE, Guire K, Giles J, Ryan K, et al. Patterns of cognitive change over time and relationship to age following successful treatment of Cushing's disease. J Int Neuropsychol Soc 2007; 13: 21-29.
7. Jeffcoate WJ, Silverstone JT, Edwards CR, Besser GM. Psychiatric manifestations of Cushing's syndrome: response to lowering of plasma cortisol. Q J Med 1979; 48: 465-472.
8. Sonino N, Fava GA. Psychiatric disorders associated with Cushing's syndrome. Epidemiology, pathophysiology and treatment. CNS Drugs 2001; 15: 361-373.
9. Sonino N, Bonnini S, Fallo F, Boscaro M, Fava GA. Personality characteristics and quality of life in patients treated for Cushing's syndrome. Clin Endocrinol 2006; 64: 314-318.
10. Hirsch D, Orr G, Kantarovich V, Hermesh H, Stern E, Blum I. Cushing's syndrome presenting as a schizophrenia-like psychotic state. Isr J Psychiatry Relat Sci 2000; 37: 46-50.
11. Tran M, Elias AN. Severe myopathy and psychosis in a patient with Cushing's disease macroadenoma. Clin Neurol Neurosurg 2003; 106: 1-4.
12. Chan LF, Vaidya M, Westphal B, Allgrove J, Martin L, Afshar F, et al. Use of intravenous etomidate to control acute psychosis induced by the hypercortisolaemia in severe paediatric Cushing's disease. Horm Res Paediatr 2011; 75: 441-446.
13. Singer E, Strohm S, Gobel U, Bieringer M, Schmidt D, Schneider W, et al. Cushing's disease, hypertension, and other sequels. Hypertension 2008; 52: 1001-1005.
14. Brown ES, J Woolston D, Frol A, Bobadilla L, Khan DA, Hanczyc M, et al. Hippocampal volume, spectroscopy, cognition, and mood in patients receiving corticosteroid therapy. Biol Psychiatry 2004; 55: 538-545.
15. Chapman C, Tubridy N, Cook MJ, Mitchell PJ, MacGregor LR, Lovelock C, et al. Short-term effects of methylprednisolone on cerebral volume in multiple sclerosis relapses. J Clin Neurosci 2006; 13: 636-638.
16. Coburn-Litvak PS, Tata DA, Gorby HE, McCloskey DP, Richardson G, Anderson BJ. Chronic corticosterone affects brain weight, and mitochondrial, but not glial volume fraction in hippocampal area CA3. Neuroscience 2004; 124: 429-438.
17. Bourdeau I, Bard C, Noel B, Leclerc I, Cordeau MP, Belair M, et al. Loss of brain volume in endogenous Cushing's syndrome and its reversibility after correction of hypercortisolism. J Clin Endocrinol Metab 2002; 87: 1949-1954.
18. Toffanin T, Nifosi F, Follador H, Passamani A, Zonta F, Ferri G, et al. Volumetric MRI analysis of hippocampal subregions in Cushing's disease: a model for glucocorticoid neural modulation. Eur Psychiatry 2011; 26: 64-67.
19. Starkman MN, Giordani B, Gebarski SS, Schteingart DE. Improvement in mood and ideation associated with increase in right caudate volume. J Affect Disord 2007; 101: 139-147.
20. Patil CG, Lad SP, Katznelson L, Laws ER Jr. Brain atrophy and cognitive defcits in Cushing's disease. Neurosurg Focus 2007; 23: E11.
21. Brunetti A, Fulham MJ, Aloj L, De Souza B, Nieman L, Oldfeld EH, et al. Decreased brain glucose utilization in patients with Cushing's disease. J Nucl Med 1998; 39: 786-790.
22. Watanabe Y, Gould E, Cameron HA, Daniels DC, McEwen BS. Phenytoin prevents stress- and corticosterone-induced atrophy of CA3 pyramidal neurons. Hippocampus 1992; 2: 431-435.
23. McEwen BS. Glucocorticoids, depression, and mood disorders: structural remodeling in the brain. Metabolism 2005; 54: 20-23.
24. Zhou J, Zhang F, Zhang Y. Corticosterone inhibits generation of long-term potentiation in rat hippocampal slice: involvement of brain-derived neurotrophic factor. Brain Res 2000; 885: 182-191.
25. Lagali PS, Corcoran CP, Picketts DJ. Hippocampus development and function: role of epigenetic factors and implications for cognitive disease. Clin Genet 2010; 78: 321-333.
26. Li Y, Tan Z, Li Z, Sun Z, Duan S, Li W. Impaired long-term potentiation and long-term memory deficits in xCT-deficient sut mice. Biosci Rep 2012; 32: 315-321.
27. Brown ES, Rush AJ, McEwen BS. Hippocampal remodeling and damage by corticosteroids: implications for mood disorders. Neuropsychopharmacology 1999; 21: 474-484.
28. Sousa N, Almeida OF. Corticosteroids: sculptors of the hippocampal formation. Rev Neurosci 2002; 13: 59-84.
29. Ambrogini P, Orsini L, Mancini C, Ferri P, Barbanti I, Cuppini R. Persistently high corticosterone levels but not normal circadian fuctuations of the hormone affect cell proliferation in the adult rat dentate gyrus. Neuroendocrinology 2002; 76: 366-372.
30. Cereseto M, Reines A, Ferrero A, Sifonios L, Rubio M, Wikinski S. Chronic treatment with high doses of corticosterone decreases cytoskeletal proteins in the rat hippocampus. Eur J Neurosci 2006; 24: 3354-3364.
31. Chameau P, Qin Y, Spijker S, Smit AB, Joels M. Glucocorticoids specifcally enhance L-type calcium current amplitude and affect calcium channel subunit expression in the mouse hippocampus. J Neurophysiol 2007; 97: 5-14.
32. Joels M, de Kloet ER. Effects of glucocorticoids and norepinephrine on the excitability in the hippocampus. Science 1989; 245: 1502-1505.
33. Polman JA, Hunter RG, Speksnijder N, van den Oever JM, Korobko OB, McEwen BS, et al. Glucocorticoids modulate the mTOR pathway in the hippocampus: differential effects depending on stress history. Endocrinology 2012; 153: 4317-4327.
34. Munhoz CD, Sorrells SF, Caso JR, Scavone C, Sapolsky RM. Glucocorticoids exacerbate lipopolysaccharide-induced signaling in the frontal cortex and hippocampus in a dose-dependent manner. J Neurosci 2010; 30: 13690-13698.
35. Vreugdenhil E, de Kloet ER, Schaaf M, Datson NA. Genetic dissection of corticosterone receptor function in the rat hippocampus. Eur Neuropsychopharmacol 2001; 11: 423-430.
36. Hansson AC, Cintra A, Belluardo N, Sommer W, Bhatnagar M, Bader M, et al. Gluco- and mineralocorticoid receptor-mediated regulation of neurotrophic factor gene expression in the dorsal hippocampus and the neocortex of the rat. Eur J Neurosci 2000; 12: 2918-2934.
37. Smith MA, Makino S, Kvetnansky R, Post RM. Stress and glucocorticoids affect the expression of brain-derived neurotrophic factor and neurotrophin-3 mRNAs in the hippocampus. J Neurosci 1995; 15: 1768-1777.
38. Rodriguez JJ, Montaron MF, Petry KG, Aurousseau C, Marinelli M, Premier S, et al. Complex regulation of the expression of the polysialylated form of the neuronal cell adhesion molecule by glucocorticoids in the rat hippocampus. Eur J Neurosci 1998; 10: 2994-3006.
39. Lopez-Figueroa MO, Itoi K, Watson SJ. Regulation of nitric oxide synthase messenger RNA expression in the rat hippocampus by glucocorticoids. Neuroscience 1998; 87: 439-446.
40. Gass P, Kretz O, Wolfer DP, Berger S, Tronche F, Reichardt HM, et al. Genetic disruption of mineralocorticoid receptor leads to impaired neurogenesis and granule cell degeneration in the hippocampus of adult mice. EMBO Rep 2000; 1: 447-451.
41. Stein-Behrens BA, Lin WJ, Sapolsky RM. Physiological elevations of glucocorticoids potentiate glutamate accumulation in the hippocampus. J Neurochem 1994; 63: 596-602.
42. Stein-Behrens BA, Elliott EM, Miller CA, Schilling JW, Newcombe R, Sapolsky RM. Glucocorticoids exacerbate kainic acid-induced extracellular accumulation of excitatory amino acids in the rat hippocampus. J Neurochem 1992; 58: 1730-1735.
43. Starkman MN, Giordani B, Gebarski SS, Berent S, Schork MA, Schteingart DE. Decrease in cortisol reverses human hippocampal atrophy following treatment of Cushing's disease. Biol Psychiatry 1999; 46: 1595-1602.